The earnings call presented a mixed picture of BICO's performance in Q2 2025. While the divestment of MatTek and Visikol significantly strengthened BICO's balance sheet, the company faced considerable challenges, particularly in the Lab Automation segment, with negative sales growth and profitability metrics. Macroeconomic conditions further impacted performance, introducing uncertainties and delayed investments. Despite strategic restructuring and operational improvements, negative trends outweighed positive developments.
Company Guidance -
Q3 2025
During the BICO earnings call for Q2 2025, the company provided several metrics and insights into its current performance and strategic direction. Sales for the second quarter amounted to SEK 324 million, reflecting a negative organic growth of 17%. The adjusted EBIT was negative SEK 49 million, with a margin of negative 15%, and cash flow from operating activities was negative SEK 28 million. The net working capital for the last 12 months of sales was 11%. Following the divestment of MatTek and Visikol to Sartorius, BICO's cash position increased significantly, with net cash from the transaction amounting to SEK 740 million, enhancing the balance sheet and reducing debt. The Lab Automation segment faced challenges with a 58% decrease in sales, largely due to project delays and fewer project starts, leading to a reestimation of project hours by around negative SEK 40 million. Conversely, the Life Science Solutions segment showed flat sales growth, aligning with industry peers. BICO is implementing strategic changes, including leadership and process enhancements, to address these issues and capitalize on the strong demand in the Lab Automation market.
Divestment of MatTek and Visikol
BICO successfully divested MatTek and Visikol to Sartorius for USD 80 million, significantly strengthening the balance sheet and resulting in a net cash position of approximately SEK 1.4 billion.
Focus on Lab Automation and Life Science Solutions
BICO implemented a new business area structure post-divestment, focusing on Lab Automation and Life Science Solutions, with positive feedback for SCIENION's growth and profitability.
Operational Excellence in Working Capital
BICO achieved a positive effect of SEK 29 million in changes in working capital, confirming successful operational excellence actions.
BICO Group AB Class B (CLLKF) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLLKF Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 19, 2025
$3.75
$2.80
-25.33%
Apr 29, 2025
$3.87
$3.74
-3.36%
Feb 19, 2025
$3.50
$3.98
+13.71%
Nov 26, 2024
$3.36
$2.76
-17.86%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BICO Group AB Class B (CLLKF) report earnings?
BICO Group AB Class B (CLLKF) is schdueled to report earning on Nov 04, 2025, TBA (Confirmed).
What is BICO Group AB Class B (CLLKF) earnings time?
BICO Group AB Class B (CLLKF) earnings time is at Nov 04, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.